GH Research (NASDAQ:GHRS) Trading Down 0.1% – Here’s What Happened

Shares of GH Research PLC (NASDAQ:GHRS) fell 0.1% during trading on Tuesday . The stock traded as low as $7.92 and last traded at $8.05. 20,530 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 79,945 shares. The stock had previously closed at $8.06.

Wall Street Analysts Forecast Growth

GHRS has been the topic of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th.

GH Research Trading Up 1.0 %

The business has a 50-day moving average price of $8.27 and a 200 day moving average price of $10.61. The stock has a market capitalization of $423.51 million, a P/E ratio of -12.98 and a beta of 0.79.

GH Research (NASDAQ:GHRS) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. On average, sell-side analysts predict that GH Research PLC will post -0.89 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its position in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,251,714 shares of the company’s stock after buying an additional 664,381 shares during the quarter. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).